The most recent print, the Q2 FY2026 results for the period ended June 30, 2026, is the load-bearing event of this report: revenue of $71.6 million, a 22% year-over-year gain, with the Minimal Residual Disease segment contributing 92% of the top line and clonoSEQ test volume up 43% to 36,111 delivered tests. The combination of a 33% MRD revenue increase, a $9.1 million MRD segment adjusted EBITDA profit (compared with $1.9 million in the prior-year quarter), and a $0.7 million consolidated adjusted EBITDA loss - within striking distance of a quarterly breakeven on a non-GAAP basis - reframes Adaptive Biotechnologies as a high-growth diagnostic franchise rather than as a struggling multi-platform biotech. The Q2 print also embeds a $23.7 million non-cash loss from the early settlement of the legacy OrbiMed revenue interest agreement, which is what drove GAAP net loss to $39.9 million. Excluding that one-time charge, the underlying net loss was $16.2 million, the smallest quarterly gap to profitability in the company's history.
We read the quarter as evidence that the equity should be valued on a single-segment basis, with the announced June 2026 plan to separate the Immune Medicine business letting the market finally mark the MRD engine at diagnostic-company multiples rather than at clinical-stage biotech multiples. The June refinancing - a $345.0 million zero-coupon convertible note due 2031 with an initial conversion price of $24.11, paired with capped call transactions and a concurrent $25.0 million share repurchase at $17.22 - eliminated the OrbiMed royalty overhang and reset the balance sheet with the capital needed to fund the separation, fund clonoSEQ commercial expansion, and absorb Immune Medicine cash burn through the divestiture process.
The single load-bearing risk is reimbursement concentration. With clonoSEQ revenue modeled as a Medicare-bundled episode payment for multiple myeloma, B-cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia patients, any adverse change to Medicare Administrative Contractor coverage, the Local Coverage Determination framework, or commercial payor reimbursement would compress the entire MRD growth story. The falsifiable clock is the next data point: the third-quarter print in early November 2026, the first reporting period that is fully unencumbered by the OrbiMed settlement, is expected to show whether the consolidated adjusted EBITDA line sustains near breakeven and whether MRD growth re-accelerates above the second-quarter sequential run rate.